Innate Pharma S.A.
IPHA
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.09
Price-1.42%
-$0.03
1Y
Price
Market Cap
$196.258m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in EUR.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$2.787m
+22.1%
1y CAGR-21.2%
3y CAGR+78.1%
5y CAGREarnings
-$49.177m
-99.0%
1y CAGR-188.5%
3y CAGR-143.9%
5y CAGREPS
-$0.53
-90.2%
1y CAGR-193.4%
3y CAGR-152.1%
5y CAGRBook Value
-$21.695m
$62.692m
Assets$84.387m
Liabilities$22.563m
DebtDebt to Assets
36.0%
-0.2x
Debt to EBITDAFree Cash Flow
-$34.910m
-790.2%
1y CAGR-261.1%
3y CAGR-179.3%
5y CAGRNo items found.
Press Releases
Statements and updates from the company